| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-117 |
Sentence |
denotes |
Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. |
| TextSentencer_T2 |
118-204 |
Sentence |
denotes |
The mechanism of drug resistance of gastric cancer cells has rarely been investigated. |
| TextSentencer_T3 |
205-342 |
Sentence |
denotes |
We specifically examine the magnitude and the biologic significance of multidrug resistance-1 (MDR-1) expression in human gastric cancer. |
| TextSentencer_T4 |
343-462 |
Sentence |
denotes |
All patients had previously been treated in prospective clinical trials for advanced gastric cancer in our institution. |
| TextSentencer_T5 |
463-655 |
Sentence |
denotes |
Patients with adequate prechemotherapy gastric cancer tissues for immunohistochemical studies by a C219 monoclonal antibody were selected for the determination of the expression rate of MDR-1. |
| TextSentencer_T6 |
656-762 |
Sentence |
denotes |
The results were designated as negative or positive by the independent interpretation of two pathologists. |
| TextSentencer_T7 |
763-918 |
Sentence |
denotes |
A subgroup of patients who had been treated with doxorubicin- or etoposide-containing regimens were selected for further correlation with drug sensitivity. |
| TextSentencer_T8 |
919-1030 |
Sentence |
denotes |
Between 1990 and 1996, a total of 60 patients, 38 men and 22 women with a median age of 55 years, were studied. |
| TextSentencer_T9 |
1031-1107 |
Sentence |
denotes |
Eight (13.3%; 95% confidence interval, 6%-25%) of them had MDR-1 expression. |
| TextSentencer_T10 |
1108-1280 |
Sentence |
denotes |
None of the pertinent clinicopathologic features, including the histopathologic types of the tumors and the extent of the diseases, correlated with the expression of MDR-1. |
| TextSentencer_T11 |
1281-1470 |
Sentence |
denotes |
Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression. |
| TextSentencer_T12 |
1471-1632 |
Sentence |
denotes |
None of the 3 patients responded to chemotherapy, whereas 19 (70.4%) of the 27 patients who had not expressed MDR-1 did respond (p=0.041 by Fisher's exact test). |
| TextSentencer_T13 |
1633-1710 |
Sentence |
denotes |
We conclude that the expression of MDR-1 in gastric cancer is relatively low. |
| TextSentencer_T14 |
1711-1911 |
Sentence |
denotes |
Its expression, however, is clinically relevant and is useful in predicting the chemoresistance of patients with gastric cancer receiving doxorubicin- or etoposide-containing combination chemotherapy. |
| T1 |
0-117 |
Sentence |
denotes |
Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. |
| T2 |
118-204 |
Sentence |
denotes |
The mechanism of drug resistance of gastric cancer cells has rarely been investigated. |
| T3 |
205-342 |
Sentence |
denotes |
We specifically examine the magnitude and the biologic significance of multidrug resistance-1 (MDR-1) expression in human gastric cancer. |
| T4 |
343-462 |
Sentence |
denotes |
All patients had previously been treated in prospective clinical trials for advanced gastric cancer in our institution. |
| T5 |
463-655 |
Sentence |
denotes |
Patients with adequate prechemotherapy gastric cancer tissues for immunohistochemical studies by a C219 monoclonal antibody were selected for the determination of the expression rate of MDR-1. |
| T6 |
656-762 |
Sentence |
denotes |
The results were designated as negative or positive by the independent interpretation of two pathologists. |
| T7 |
763-918 |
Sentence |
denotes |
A subgroup of patients who had been treated with doxorubicin- or etoposide-containing regimens were selected for further correlation with drug sensitivity. |
| T8 |
919-1030 |
Sentence |
denotes |
Between 1990 and 1996, a total of 60 patients, 38 men and 22 women with a median age of 55 years, were studied. |
| T9 |
1031-1107 |
Sentence |
denotes |
Eight (13.3%; 95% confidence interval, 6%-25%) of them had MDR-1 expression. |
| T10 |
1108-1280 |
Sentence |
denotes |
None of the pertinent clinicopathologic features, including the histopathologic types of the tumors and the extent of the diseases, correlated with the expression of MDR-1. |
| T11 |
1281-1470 |
Sentence |
denotes |
Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression. |
| T12 |
1471-1632 |
Sentence |
denotes |
None of the 3 patients responded to chemotherapy, whereas 19 (70.4%) of the 27 patients who had not expressed MDR-1 did respond (p=0.041 by Fisher's exact test). |
| T13 |
1633-1710 |
Sentence |
denotes |
We conclude that the expression of MDR-1 in gastric cancer is relatively low. |
| T14 |
1711-1911 |
Sentence |
denotes |
Its expression, however, is clinically relevant and is useful in predicting the chemoresistance of patients with gastric cancer receiving doxorubicin- or etoposide-containing combination chemotherapy. |